Cryoport reports FY 2024 revenue $228.4M (-2% YoY); guides FY 2025 revenue $240-250M

Cryoport, Inc.

FY 2024 revenue $228.4M (down 2% YoY); Q4 revenue $59.5M (up 4% YoY).
Net loss attributable to common shareholders FY 2024 $122.8M ($2.49/sh) vs $107.6M ($2.21/sh) in FY 2023.
Commercial Cell & Gene therapy revenue grew 20% YoY to $25.9M in FY 2024.
Adjusted EBITDA negative $15.1M in FY 2024 vs negative $8.3M in FY 2023.
FY 2025 revenue guidance $240M-$250M; gross margin improved to 45.8% in Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.